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Objectives. Considerable evidence exists for the use of arm vein conduit in lower limb bypass surgery. The use of arm vein
in preference to synthetic conduit as a last autogenous option was assessed for patency and limb salvage outcomes.
Materials and methods. A prospective database was interrogated and checked against TQEH operating theatre database
to detect all infrainguinal arm vein bypasses performed between 1997 and 2005. Patency, limb salvage and survival data
for 37 arm vein bypasses was calculated using the Kaplan-Meier survival estimate method.
Results. There were no perioperative deaths. 30 day patency rates were 89% primary, 95% secondary and 95% limb
salvage. 12 month patency rates were 56% primary, 79% secondary and 91% limb salvage. 5 year patency rates were
37% primary, 76% secondary and 91% limb salvage. There was no significant patency advantage for primary vs. ‘‘redo’’
grafts (p¼ 0.54), single vessel vs. spliced conduits (p¼ 0.33) or popliteal vs tibial outflow (p¼ 0.80). Patient survival
rate was 92% and 65% at 1 and 5 years respectively.
Conclusion. Lower limb bypasses using arm vein can be performed with favourable patency and limb salvage compared
to synthetic conduits. However, secondary interventions are frequently required to maintain patency. We recommend a
vigilant surveillance program for early identification of patency threatening disease.
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Great saphenous vein (GSV) is the preferred vascular
conduit for infra-inguinal bypass grafting because it
has proven thrombo-resistance and long term durabil-
ity when compared to other grafts.1e3 In 20e25% of
people ipsilateral GSV is unavailable because of ab-
sence or unsuitability.4,5 Commonly used alternative
conduits include autogenous small saphenous (SSV)
and arm vein both of which may be a single vein seg-
ment or spliced. Synthetic and biological substitute
grafts are often readily available and save time in prep-
aration. The majority of surgeons on our unit have
practiced an ‘‘all-autogenous’’ policy, preferring to use
arm vein in preference to synthetic grafts when either
GSV or SSV is unavailable. Autogenous conduit is
preferred to reduce graft infection rates and improve
patency whilst achieving the goal of limb salvage.
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by Kakkar in 1969.6 Since that time there have been
a number of large case series from centres that prac-
tice arm vein bypass as the first alternative for infra-
inguinal bypass surgery when ipsilateral GSV is not
available.7e9 These show excellent medium to long
term patency, however may not reflect the practice
of centres that prefer to exhaust other autogenous
options before utilising arm vein.
Many vascular centres use contralateral GSV or SSV
as the first alternatives to ipsilateral GSV and use arm
vein only as a last autogenous option. By this time pa-
tients have had multiple hospitalisations and often
arm vein instrumentation and cannulation. These cen-
tres seek to establish whether last autogenous option
arm vein bypasses are indeed superior to the alter-
native poly-tetra-fluoro-ethylene (PTFE) and Dacron
synthetic conduits with and without vein cuffs, and
those newer conduits bonded with heparin.10
The aim of this series is to present data from a busy
vascular surgical unit that has used arm vein conduit
as a last autogenous option, to provide generalisableerved.
738 R. L. Varcoe et al.patency and limb salvage information for comparison
with synthetic grafts.
Materials and Methods
Between May 1997 and August 2005 a consecutive
series of patients undergoing infrainguinal arterial
reconstruction for arterial occlusive disease at The
Queen Elizabeth Hospital were recorded prospectively
in a computerised database. The database included
patient demographics, procedure and outcome data.
To ensure complete detection of cases the HAS Opera-
ting Theatre database was also searched using the
relevant codes to identify all infrainguinal bypass oper-
ations performed. Every operation note was hand
searched for the use of arm vein conduit. Data was
then collected retrospectively using a standardized
datasheet encompassing clinical data which included
presenting symptoms, investigation findings, opera-
tion details, and follow up.
Over this period 37 infrainguinal arterial recon-
structions with arm vein conduit were performed on
36 limbs in 35 patients (63% male) for the treatment
of lower extremity ischaemia. Patient demographic
data is presented in Table 1. The indication was limb
salvage (89%) or disabling claudication (11%) in the
absence of suitable ipsilateral or contralateral GSV or
SSV in all cases (54% previous lower limb surgery,
41% inadequate length or calibre of vein, 5% previous
coronary grafting). In 21 (57%) cases the surgery was
for first bypass grafts and 16 (43%) were ‘‘redo’’ oper-
ations for failed previous grafts, 3 (8%) of which were
skip grafts from earlier bypasses. Patients ranged in
age from 55 to 84 years with a median age of 73 years.
Preoperative duplex mapping was used routinely
to assess conduit suitability and mark the veins.
They were then harvested as previously described
through continuous upper limb incisions.9 Vein ab-
normalities were either patched or resected and
when required for length veno-venostomy was per-
formed in the standard fashion with a continuous
Table 1. Patient demographics
Characteristic Percentage (n¼ 35)
Male/Female 63/37
Hypertension 74
Hypercholesterolaemia 57
COPD 49
Diabetes Mellitus 40
Chronic Renal Failure 17
Cardiac Failure 6
Ischemic Heart Disease 37
Current/Ex Smoker 60
Prothrombotic Disorder 6
COPD, Chronic Obstructive Pulmonary Disease.Eur J Vasc Endovasc Surg Vol 33, June 20077e0 polypropylene suture. The graft was gently dis-
tended and kept in a cool, balanced heparin/normal
saline solution to maintain endothelial integrity.
Grafts were reversed without exception before anasto-
mosis from inflow to outflow vessel as described in
Table 2. Completion angiography was performed
with any irregularities identified and corrected at
the time of surgery. The grafts consisted of either sin-
gle vessel arm vein segments or spliced arm to arm
vein or GSV (Table 3).
Follow up was performed post-operatively at 3
months, then 6 months for 2 visits and 12 monthly
thereafter. Patency was assessed by means of routine
clinical assessment, ankle-brachial indices and colour
flow duplex ultrasound with selective use of digital
subtraction angiography. This was completed within
the environment of a formalised surveillance clinic.
Follow up data was obtained from hospital records,
outpatient charts, and from individual surgeons pri-
vate practices. All definitions and categories were
from the Ad Hoc Committee on Reporting Standards
appointed by the Society of Vascular Surgery, and
the North American chapter of the International Soci-
ety of Cardiovascular Surgery.11 The follow up period
ranged from 2 to 72 months, with an average of 26
months.
Graft patency, limb salvage and survival were cal-
culated using the Kaplan-Meier survival estimate
method. Comparison between survival curves was per-
formed using the log-rank test for significance. Figures
were presented as mean value standard error. A
P value of less than 0.05 was considered significant.
Results
Mortality and complication rates. There was no peri-
operative mortality. Perioperative morbidity is listed
in Table 3. There were six (16%) unplanned returns
to theatre for haematoma evacuation (2), graft
Table 2. Graft configuration for inflow and outflow vessels
Graft Inflow Artery Number (%)
External Iliac 2 (5)
Common Femoral 15 (41)
Profunda Femoris 6 (16)
Superficial Femoral 8 (22)
Popliteal 3 (8)
Previous Vein Graft 3 (8)
Graft Outflow Artery
Profunda Femoris 1 (3)
Superficial Femoral 0
Popliteal Above Knee 2 (5)
Popliteal Below Knee 14 (38)
Tibial 15 (41)
Pedal 5 (14)
739Last Resort Arm Vein for Infrainguinal Bypass Surgerythrombectomy (2), wound debridement (1) and major
amputation after graft thrombosis (1).
Patency and limb salvage. The primary patency, sec-
ondary patency, limb salvage and survival rates are
presented in Fig. 1. Thirty day patency rates were
primary 89% 5%, secondary 95% 4% and limb
salvage 95% 4%. Twelve month patency rates were
primary 56% 9%, secondary 80% 7% and limb
salvage 91% 5%. Five year patency rates were primary
37% 9%, secondary 76% 8% and limb salvage
91% 5%.
Ten grafts were revised before occlusion. There were
eight simple patch angioplasties and one interposition
graft for stenosis, while the final graft underwent 3
separate patch angioplasties and an interposition graft
at different time points to remain patent at the time of
patient’s death. Of the 8 grafts that occluded only 2
were revised. One had a simple thrombectomy remain-
ing patent for another twenty-four hours; the other
underwent thrombectomy and interposition graft
remaining patent for the remaining sixteen month
follow up.
Table 3. Perioperative morbidity
Morbidity Percentage (n¼ 35)
Wound Haematoma 8
Myocardial Infarction 5
Cardiac Arrhythmia 10
Pneumonia 8
Renal Dysfunction 5
Urinary Tract Infection 3
Partial Lower Limb Wound Dehiscence 11
Area of Arm Paraesthesia 3
Cellulitis 3
Oedema 3
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Fig. 1. Kaplan-Meier analysis displaying limb salvage, pri-
mary and secondary patency rates for all 37 arm vein bypass
grafts.Patency rates in first bypass operations were com-
pared with those for redo surgery. There was no primary
(p¼ 0.54, hazard ratio 1.31, 95% CI 0.54 to 3.20) or sec-
ondary patency advantage (p¼ 0.62, hazard ratio 0.70,
95% CI 0.17 to 2.83) seen in these first bypass grafts.
There were similar proportions of single vessels
and spliced vessels used as conduit (Table 4). There
was a trend towards improved secondary patency
with single vessel conduits (Fig. 2) however this was
not significant (p¼ 0.33, hazard ratio 1.99, 95% CI:
0.49 to 8.07). Patency rates were higher for grafts
whose outflow vessel was the popliteal artery rather
than a tibial vessel, however these differences were
also not significant (Primary p¼ 0.80, hazard ratio
1.12, 95% CI 0.44 to 2.88; Secondary p¼ 0.67, hazard
ratio 0.73, 95% CI 0.16 to 3.22).
The overall patient survival rate was 92% and 65%
at 1 and 5 years respectively (Fig. 3). The median sur-
vival was 72 months post bypass surgery.
Discussion
A number of centres have published data with arm
vein patency rates superior to synthetic grafts when
used as a primary alternative to ipsilateral GSV.7e9
They use angioscopy to painstakingly inspect each
arm vein for valve lysis and irregularities that may re-
duce patency. This process is time consuming and
their results may not reflect those in the wider vascu-
lar community.
There remains considerable concern over the fragile
nature, frequent endothelial irregularities and iatro-
genic trauma and stenoses seen with arm vein con-
duit.12 Iatrogenic trauma is common with more
frequent admissions to hospital as with multiple
redo bypass surgery. In addition arm vein segments
may provide insufficient length necessitating one or
more veno-venostomies which some authors believe
reduces patency.13,14
These concerns have led to several authors postula-
ting that synthetic grafts may provide a less time
consuming option that combined with various pa-
tency manoeuvres rivals the durability of ‘‘last resort’’
arm vein grafts. Despite the more convenient nature
of these grafts a multitude of large randomised trials
Table 4. Arm vein characteristics
Conduit Number (%)
Single Vessel (Ceph, Brach or Basilic) 20 (54)
Arm Vein/Arm Vein e Spliced 8 (22)
Arm Vein/GSV e Spliced 9 (24)
Ceph, Cephalic vein; Brach, Brachial vein; GSV, Great Saphenous
Vein.Eur J Vasc Endovasc Surg Vol 33, June 2007
740 R. L. Varcoe et al.have seen conventional synthetic grafts under-
perform when compared to our arm vein patency and
limb salvage rates.15e17 A multicentre trial by Devine
et al. randomised 209 patients to heparin bonded da-
cron (HBD) or conventional expanded PTFE.10 They
found no difference in secondary patency rates bet-
ween the two groups at 5 years and both were inferior
to our arm vein rates (HBD 47%, ePTFE 36%: Arm
vein 75.6%). Limb salvage was also examined and
again found to be reduced when compared to our se-
ries (HBD 86% vs. ePTFE 74%; p< 0.025: Arm vein
91%). Stonebridge et al. examined the effect of ePTFE
with vein cuff in 261 above and below knee femoropo-
pliteal bypass grafts.18 Although their 12 month pa-
tency rates for above knee grafts were equivalent to
ours at 80%, by 2 years this had dropped to 72% be-
low our 5 year patency of 76%. Below knee grafts
were again equivalent at 12 months with a patency
of 80% however considerably inferior by 2 years
with a patency of 52%. In addition limb salvage was
lower in their series at 84% after 2 years compared
with our 91% after 5 years.
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Fig. 2. Kaplan-Meier analysis displaying no difference in
secondary patency rates between spliced and single vessel
graft conduits (p¼ 0.33).
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Fig. 3. Kaplan-Meier analysis of survival post arm vein
bypass surgery.Eur J Vasc Endovasc Surg Vol 33, June 2007Almost half of arm vein bypasses we performed
were for redo operations. This reflects the unit ap-
proach of using arm vein as the last available auto-
genous option. There was no patency reduction with
redo grafts compared with primary grafts despite
the more technically challenging nature of the dissec-
tion and the presumed inferiority of the inflow and
outflow vessels which may have been responsible
for previous graft failure. This finding is consistent
with previous studies suggesting that quality of con-
duit is a more important factor than previous surgery
influencing patency.7,19
Our patency figures demonstrated a trend towards
improvement with single length vein conduit over
spliced vein. This difference was not statistically sig-
nificant. Other studies have demonstrated such an ad-
vantage and it may be that as our experience grows
this small difference will reach significance.7,20 If so
it is probably a consequence of poor vein quality
rather than problems relating to the veno-venostomy
which were not a feature in our series.
The difference in primary and secondary patency
rates serves to emphasise how effectively patency
can be preserved by vigilant surveillance, repair and
revision. Many authors consider that the ongoing
patency of the graft and a functional healed limb are
the critical endpoints, discounting the inconvenience
of patency interventions.21,22 This is because of the
quality of life benefits that ensue from an intact
limb. These functional endpoints are best reflected
in our outcome measures of secondary patency and
limb salvage, which remain excellent despite poor
primary patency. Economically it would seem that
cost too favours limb salvage surgery with Wixon
et al. finding that the 5 year cost of infrainguinal
bypass grafting, surveillance and revision was less
than or equal to the cost of primary amputation.23
A number of authors have demonstrated that up to
74% of arm vein bypasses have some form of intra-
luminal abnormality detected when inspected with
angioscopy.24,25 This may be partly responsible for
the high rate of reinterventions that were required in
our series despite the routine use of completion angio-
graphy. Our results have demonstrated that with pre-
operative duplex mapping, completion angiography
and careful graft surveillance excellent graft patency
and limb salvage can be achieved without the use of
routine angioscopy.
The revisions performed in our series were all open
surgical, either patch angioplasties, interposition
grafts or thrombectomies. The authors are not averse
to using endovascular methods to overcome patency
threatening lesions however we feel that arm vein
stenoses are often complicated lesions lending
741Last Resort Arm Vein for Infrainguinal Bypass Surgerythemselves to definitive surgical correction to avoid
recurrent stenoses. Many large series have success-
fully used predominantly open surgical repair26 and
others have noted the need for repeated treatments
when endovascular techniques are used27,28 lending
support to this centre’s practice.
In such a lengthy procedure the authors have found
it useful to have dual operating teams. One team
harvests and prepares the arm vein whilst the second
exposes the inflow and outflow vessels then performs
the anastomoses. This significantly reduces the operat-
ing time making the procedure eminently manageable.
Adequate patency and limb salvage rates can be
achieved with single vessel or spliced arm vein by-
pass grafts for both primary and redo surgery. The
high rates of limb salvage demonstrable with arm
vein redo bypass should serve to reinforce the value
of infrainguinal revascularisation over amputation
even in the absence of GSV. Good quality autogenous
vein is the best conduit for these bypasses and effort
should be made to harvest and prepare any and all
alternative vein present.
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